fashion -WSS

fashion

author：Wikipedia 2025-09-30 00:49:31 - browse：75

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Chronically ill young patients struggle to find fertility info

focus

WSS

U.K. sequencing study surfaces new findings about tumor DNA

What will Novo Nordisk's VC do with its influx of cash?

Goldman Sachs launches $650M fund for life science investments

Flu, Covid vaccination rates decline, new survey data show

The FDA must approve intranasal treatments for anaphylaxis

Study points to new risk in gene therapy death of Terry Horgan

focus

fashion

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Will an HIV vaccine ever be a reality?

Moonlake's readout produced a cash windfall. Risks remain

Lawsuit highlights wrinkle for disputes over surprise medical bills

Guidelines to prevent youth baseball injuries need more muscle

AdventHealth escalates lawsuit against insurance vendor Multiplan

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New oral drug delivery patch is modeled after octopus tentacles

Guidelines to prevent youth baseball injuries need more muscle

Will an HIV vaccine ever be a reality?

focus

Antibiotic resistance and the global rise in human conflict

Nobel honors Karikó and Weissman's enduring partnership

6 solutions to address cancer drug shortages and others

Videos point to link between seizures and unexplained toddler deaths

WHO recommends second malaria vaccine

J&J to buy cancer drug developer Ambrx Biopharma

focus

explore

focus

explore